Harald Arnesen Selected Research

Stroke (Strokes)

1/2022	Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial.
9/2021	Serum Levels of Dihomo-Gamma (γ)-Linolenic Acid (DGLA) Are Inversely Associated with Linoleic Acid and Total Death in Elderly Patients with a Recent Myocardial Infarction.
10/2018	Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction.
1/2017	Early discharge compared with ordinary discharge after percutaneous coronary intervention - a systematic review and meta-analysis of safety and cost.
1/2016	Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction.
4/2012	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
6/2010	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
1/2010	Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction).
1/2010	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
12/2004	Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harald Arnesen Research Topics

Disease

53	Myocardial Infarction 04/2022 - 09/2002
35	ST Elevation Myocardial Infarction 04/2022 - 07/2005
27	Coronary Artery Disease (Coronary Atherosclerosis) 12/2022 - 10/2002
24	Atrial Fibrillation 01/2022 - 06/2007
21	Atherosclerosis 01/2022 - 01/2002
20	Thrombosis (Thrombus) 04/2022 - 02/2003
17	Infarction (Infarctions) 04/2022 - 10/2003
16	Coronary Disease (Coronary Heart Disease) 08/2020 - 01/2002
12	Heart Failure 04/2022 - 01/2009
12	Inflammation (Inflammations) 09/2020 - 11/2006
11	Stroke (Strokes) 01/2022 - 09/2002
11	Type 2 Diabetes Mellitus (MODY) 12/2021 - 03/2010
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 03/2009
10	Hemorrhage 01/2022 - 09/2002
8	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 01/2004
6	Hypertension (High Blood Pressure) 09/2021 - 04/2007
6	Thrombophilia 12/2020 - 08/2012
5	Heart Diseases (Heart Disease) 09/2020 - 04/2012
5	Stable Angina 01/2017 - 11/2009
5	Acute Coronary Syndrome 04/2016 - 01/2010
4	Necrosis 12/2021 - 01/2013
3	Glucose Intolerance 10/2019 - 01/2009
3	Insulin Resistance 01/2019 - 04/2007
3	Hyperlipidemias (Hyperlipidemia) 01/2016 - 03/2005
3	Ischemia 03/2014 - 01/2010
2	Diabetes Mellitus 09/2021 - 12/2012
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 01/2020
2	Albuminuria 01/2019 - 01/2017
2	Vascular Diseases (Vascular Disease) 01/2019 - 01/2016

Drug/Important Bio-Agent (IBA)

15	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017 - 09/2002
12	Biomarkers (Surrogate Marker)IBA 12/2021 - 05/2002
11	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 12/2021 - 03/2005
11	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2009
9	Interleukin-18 (Interleukin 18)IBA 01/2019 - 03/2009
8	Troponin T (Troponin T1)IBA 01/2021 - 07/2014
8	Thromboplastin (Tissue Factor)IBA 01/2020 - 01/2003
8	Thrombin FDA Link 10/2018 - 02/2003
7	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022 - 01/2005
7	Interleukin-6 (Interleukin 6)IBA 01/2021 - 11/2011
7	fibrin fragment D (D-dimer)IBA 10/2018 - 04/2006
7	AnticoagulantsIBA 04/2016 - 02/2003
7	candesartanIBA 01/2016 - 06/2007
7	Clopidogrel (Plavix)FDA Link 08/2012 - 12/2004
6	pro-brain natriuretic peptide (1-76)IBA 12/2022 - 01/2009
6	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 11/2009
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2008
6	Prothrombin (Factor II)IBA 10/2018 - 01/2010
6	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 06/2012 - 02/2003
6	Warfarin (Coumadin)FDA LinkGeneric 04/2012 - 09/2002
5	Tissue Inhibitor of Metalloproteinase-1IBA 01/2022 - 01/2012
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2011
5	Insulin (Novolin)FDA Link 01/2020 - 04/2007
5	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2018 - 01/2010
5	Chemokine CX3CL1IBA 01/2016 - 12/2012
5	Nitric Oxide Synthase (NO Synthase)IBA 02/2011 - 02/2003
4	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2022 - 03/2005
4	Peroxidase (Myeloperoxidase)IBA 01/2020 - 12/2015
4	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018 - 01/2009
4	Tissue Inhibitor of MetalloproteinasesIBA 01/2018 - 11/2009
4	Trinitrotoluene (TNT)IBA 05/2016 - 01/2014
4	CytokinesIBA 01/2016 - 03/2010
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 08/2012 - 12/2004
4	Arginine (L-Arginine)FDA Link 02/2011 - 02/2003
3	Plasminogen Activator Inhibitor 1IBA 04/2022 - 01/2008
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2017
3	apixabanIBA 01/2022 - 04/2012
3	Eicosapentaenoic AcidIBA 01/2022 - 09/2020
3	Docosahexaenoic AcidsIBA 01/2022 - 01/2016
3	Phospholipids (Phosphatides)FDA LinkGeneric 09/2021 - 01/2004
3	Galectin 3 (LGALS3)IBA 08/2021 - 12/2015
3	AcidsIBA 01/2021 - 06/2008
3	Fatty Acids (Saturated Fatty Acids)IBA 09/2020 - 10/2002
3	Interleukin-8 (Interleukin 8)IBA 01/2020 - 01/2014
3	Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA 01/2019 - 01/2014
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 10/2010
3	Troponin IIBA 09/2018 - 01/2016
3	Vitamin K FDA Link 04/2016 - 04/2012
3	Cytokine Receptor gp130IBA 01/2016 - 07/2013
3	C-Reactive ProteinIBA 01/2016 - 09/2012
3	Angiotensin II Type 1 Receptor BlockersIBA 01/2016 - 08/2007
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2016 - 01/2013
3	MB Form Creatine KinaseIBA 01/2016 - 12/2010
3	CD40 Ligand (CD40L)IBA 12/2015 - 09/2012
3	Tenecteplase FDA Link 08/2014 - 01/2010
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2013 - 11/2009
2	Plasminogen Activators (Plasminogen Activator)IBA 04/2022 - 01/2013
2	Enoxaparin (Lovenox)FDA LinkGeneric 01/2022 - 01/2010
2	AdiponectinIBA 12/2021 - 07/2010
2	Linoleic Acid (Linoleate)IBA 09/2021 - 12/2019
2	Corn Oil (Oil, Corn)IBA 01/2021 - 01/2006
2	InflammasomesIBA 01/2021 - 01/2019
2	Sirtuin 1IBA 08/2020 - 01/2019

Therapy/Procedure

25	Percutaneous Coronary Intervention 01/2017 - 04/2004
14	Therapeutics 01/2017 - 09/2002
9	Stem Cell Transplantation 09/2014 - 07/2005
8	Electric Countershock (Cardioversion) 01/2016 - 06/2007
4	Patient Readmission 10/2018 - 01/2016
4	Secondary Prevention 04/2012 - 09/2002
3	Stents 06/2010 - 11/2009
2	Glycemic Control 01/2020 - 01/2020